Phase 1 N=9 Single DermaVir Immunization in HIV-1 Infected Patients on HAART
HIV Infection
Primary: Grade 3 Adverse Event Related to DermaVir Treatment — 0; 0; 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=182 Immunogenicity of Hepatitis B Vaccination in HIV-infected Adults
Hepatitis B Vaccine
Primary: Number and Percentage of Participants With Anti-HBs Seroconversion at Month 7 — 75; 69 Participants
Phase 1 N=33 Therapeutic Vaccine for HIV
HIV · Therapeutic Vaccine
Primary: The Rate of Related Adverse Events in Subjects Who Began cART During Acute or Early HIV-1 Infection. — 0; 0 Related Adverse Events
Phase 1 N=23 HIV-1 Peptide Immunisation of Individuals in West Africa to Prevent Disease
Aids, Cdc Group I
Primary: Tolerability and Safety of the Treatment. — 0; 0 participants
Phase 2 N=92 Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers
HIV Infection
Primary: Evaluation of the Safety of MVA HIV-B at Week 2 in Arm 1 — 22 Participants
Phase 2 N=319 Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
HIV Infections · Sexually Transmitted Diseases
Primary: Percentage of Participants With HPV6 Antibody Development From Seronegative Status at Baseline to Seropositive Status a Month After Completion of HPV Vaccination Series…
Phase 4 N=16 HIV Persistence and Viral Reservoirs
HIV · HIV Infections
Primary: Mean Change in Estimated Ultrasensitive Plasma HIV RNA Levels Between Baseline and Week 24 — 66 fold decrease in signal/cutoff ratio
Phase 2 N=11 Autologous Dendritic Cell Vaccine in HIV1 Infection
HIV Infections
Primary: Safety and Tolerability of Autologous HIV-1 ApB DC Vaccine. — 2 participants with Grade 3 events related
Phase 2 N=28 Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir
HIV Infection
Primary: Change From Baseline in HIV DNA in PBMCs at Week 56 — 0.00; 0.04 log^10 copies per 10^6 PBMCs
Phase 4 N=546 Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
Infections, Papillomavirus · Papillomavirus Vaccines
Primary: Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms — 115; 58; 4; 0 Participants
Phase 2 N=252 A Safety and Immune Response Study of 2 Experimental HIV Vaccines
HIV Infection
Primary: Part A: Number of Participants Reporting Local Reactogenicity Signs and Symptoms During the Primary Vaccine Regimen — 42; 26; 126; 16 Participants
Phase 2 N=133 Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults
Dengue Fever · Dengue Hemorrhagic Fever · Human Immunodeficiency Virus
Primary: Percentage of Participants With Unsolicited Systemic Adverse Event (AE) — 0; 0 percentage of participants
Phase 2 N=99 Impact of a Human Papilloma Virus (HPV) Vaccine in HIV-Infected Young Women
HIV Infection
Primary: HPV-6 Antibody Level (Geometric Mean Titer of HPV-6) — 738.9 Milli-Merck units/milliliter (mMU/mL)
Phase 4 N=195 Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals
HIV Infection
Primary: Immunogenicity — 22; 25; 344; 686 Geometric Mean antibody titer
Phase 2 N=109 Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection
Infection · Precancerous Condition
Primary: Occurrence of ≥ Grade 3 Adverse Events Probably or Definitely Related to the Vaccine — 0 participants
Phase 4 N=56 Mechanisms of Lipodystrophy in HIV-Infected Pateints
HIV Infections
Primary: Effect of Drug Regimens on Serum Triglycerides. — 228.0; 230.4; 293.4; 290.0 mg/dL — p=0.94
Phase 2 N=231 Intradermal Versus Intramuscular Polio Vaccine Booster in HIV-Infected Subjects
Polio Immunity
Primary: Post Booster Polio Neutralizing Antibody Titers — 1715; 976; 1249; 1328 antibody titers
Phase 2 N=581 Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients
HIV Infections
Primary: Serious Adverse Events — 0; 17; 0; 6 Participants
Phase 3 N=20 Dipeptidyl Peptidase-4 Inhibition and Immune Function in HIV
Diabetes · Insulin Resistance
Primary: CD4+ T-cell Count — 602; 648; 689; 750 cells/µL — p=>0.05
Phase 1 N=65 A Safety and Immunogenicity Trial of IHV01
HIV Infection
Primary: Number of Participants With Local and Systemic Reactogenicity Signs and Symptoms — 3; 8; 4; 5 Participants
Phase 3 N=407 Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED)
Pneumococcal Infections
Primary: Percentage of Participants With a Solicited Injection-Site Adverse Event Following Vaccination With V114 or Prevnar 13™ — 9.4; 5.9; 10.3; 6.4 Percentage of Participants
Phase 2 N=136 Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIV
HIV I Infection
Primary: Proportion of Subjects Who Require Resumption of ART Between the Interruption of ART at Week 28 and End of Study at Week 52. — 88; 40; 88; 38 participants
Phase 4 N=371 Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth
HIV Infection · Hepatitis B
Primary: Sero-response to Hepatitis B Surface Antigen — 60; 73.2; 75.4 percentage of participants who resonded — p=0.0440
N/A N=120 HIV And Parasitic Infection (HAPI) Study
HIV Coinfection
Primary: Number of Participants With and Without Intestinal Parasitic Infection — 36; 84 Participants
Phase 2 N=149 Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males
Anal Cancer · Nonneoplastic Condition · Penile Cancer
Primary: Incidence of AIN or Anal/Perianal Condyloma Associated With HPV 6 DNA — 0.0; 11.1 Events per 100 person years — p=0.112
Phase 2 N=58 ARVs to Prevent Breastmilk HIV:Viral and Immune Responses
HIV Infections
Primary: Outcome 1: Serial HIV-1 RNA Levels in Breastmilk. — 2.74; 2.03; 1.70; 1.70 Log10 Viral load copies/ml
Phase 1 N=60 Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults
HIV Infections
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms — 2; 5; 5; 3 Participants
Phase 3 N=302 A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)
Pneumococcal Infections
Primary: Percentage of Participants With a Solicited Injection-site Adverse Event After Vaccination 1 — 4.6; 3.3; 57.2; 51.3 Percentage of Participants
Phase 2 N=126 Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
HIV Infections · Sexually Transmitted Diseases
Primary: Percent of Participants Developing Grade 3 or 4 Adverse Events (AEs) — 7.3; 6.7 percent of participants — p=1.00
Phase 3 N=313 Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)
Pneumococcal Disease
Primary: Percentage of Participants With Solicited Injection-site AEs From Day 1 Through Day 5 Postvaccination in Part A — 3.9; 11.0; 50.3; 82.6 Percentage of Participants